The InhiBETTM Platform: Bromodomain and End Terminal (BET) Inhibitors in Autoimmune Disease

Time: 11:00 am
day: Day One


  • Review BET protein antagonism and MoA in autoimmune disease, what have we learned?
  • Explore drug design and disposition strategies to optimize benefit/risk of BET inhibitors
  • Introducing VYN201, a highly potent BD1/BD2 BET protein inhibitor, for locallyacting treatment of major immuno-inflammatory